Tech Center 1600 • Art Units: 1641
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17996338 | IMMUNOCONJUGATES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18257793 | NUCLEIC ACIDS ENCODING ANCHOR MODIFIED ANTIBODIES AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18260125 | ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF | Non-Final OA | Eli Lilly and Company |
| 17436939 | T CELL RECEPTORS AND METHODS OF USE THEREOF | Final Rejection | University Health Network |
| 17604559 | MRNA FORMULATION | Non-Final OA | Vrije Universiteit Brussel |
| 18000312 | Dual EGFR-MUC1 Chimeric Antigen Receptor T Cells | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18276916 | ANTI-LAIR1 ANTIBODIES FOR THE TREATMENT OF CANCER | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 17783345 | ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF | Final Rejection | University of Florida Research Foundation, Incorporated |
| 17631588 | MULTI-VALENT AND MULTI-SPECIFIC NANOPARTICLE PLATFORMS AND METHODS | Final Rejection | The Governing Council of the University of Toronto |
| 17746112 | VACCINE AND METHOD FOR TREATING CANCER | Final Rejection | China Medical University |
| 18021323 | LFA-1 SIGNALLING MEDIATOR FOR USE IN CANCER THERAPY | Non-Final OA | Universität Basel |
| 17996802 | SINGLE VARIABLE DOMAIN ANTIBODY TARGETING HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1) AND DERIVATIVE THEREOF | Non-Final OA | MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. |
| 17634631 | 4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS, ANTIBODIES AGAINST 4-1BB, ANTIBODIES AGAINST OX40 | Non-Final OA | Aptevo Research and Development LLC |
| 18089493 | DOUBLE PAYLOAD CANCER THERAPEUTICS | Non-Final OA | Aarvik Therapeutics, Inc. |
| 17606454 | PRECURSOR TRI-SPECIFIC ANTIBODY CONSTRUCTS AND METHODS OF USE THEREOF | Non-Final OA | Immunorizon Ltd. |
| 17779425 | ANTI-PD-1-ANTI-VEGFA BISPECIFIC ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Non-Final OA | AKESO BIOPHARMA, INC. |
| 17811455 | ANTI-TIGIT ANTIBODIES AND METHODS OF USE | Non-Final OA | SHANGHAI HENLIUS BIOTECH, INC. |
| 17763344 | PD-L1 TARGETED CHIMERIC PROTEINS AND USES THEREOF | Final Rejection | Orionis Biosciences, Inc. |
| 17636699 | ANTI-CD19 ANTIBODIES AND USES THEREOF | Non-Final OA | Elpis Biopharmaceuticals |
| 17629295 | CD63 AGONIST-RELATED METHODS AND COMPOSITIONS | Non-Final OA | AgonOx, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy